Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:1749
Name squamous cell carcinoma
Definition A carcinoma that derives_from squamous epithelial cells.
Source DiseaseOntology.org
Alt Ids DOID:5512
Path disease disease of cellular proliferation cancer cell type cancer carcinoma squamous cell carcinoma


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA mutant Carboxyamidotriazole Orotate squamous cell carcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00770263 Phase I Erlotinib + Temsirolimus Erlotinib and Temsirolimus for Solid Tumors Completed USA 0
NCT02383927 Phase II Tipifarnib Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations Completed USA | ITA | FRA | ESP | DEU | BEL 4
NCT02723955 Phase I GSK3359609 GSK3359609 + Pembrolizumab Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) Active, not recruiting USA | ITA | FRA | ESP | CAN 4
NCT03357757 Phase II Avelumab + Valproic acid Avelumab With Valproic Acid in Virus-associated Cancer (LATENT) Recruiting CAN 0
NCT03391973 Phase II Pembrolizumab Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) (CUP) Recruiting CAN 0
NCT03396471 Phase II Pembrolizumab Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary Active, not recruiting USA 0
NCT03590054 Phase I Abexinostat + Pembrolizumab Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies Active, not recruiting USA 0
NCT03669718 Phase II Cemiplimab + ISA101b Cemiplimab A Randomized Phase 2 Study of Cemiplimab +/- ISA101b in HPV16-Positive OPC Recruiting USA | ITA | FRA | ESP | DEU | BEL 7
NCT03786237 Phase Ib/II Rigosertib Rigosertib for RDEB-SCC Recruiting AUT 0
NCT04131621 Phase II Nivolumab Ipilimumab Ipilimumab + Nivolumab Nivolumab/Ipilimumab in Second Line CUP-syndrome (CheCUP) Unknown status DEU 0
NCT04666688 Phase Ib/II LYT-200 LYT-200 + unspecified PD-1 antibody Gemcitabine + LYT-200 + Nab-paclitaxel LYT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors Recruiting USA 0
NCT04714983 Phase I DNX-2440 DNX-2440 for Resectable Colorectal Liver Metastasis Recruiting USA 0
NCT05472220 Phase I Alpelisib + Carboplatin Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma Withdrawn 0